Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spanish experience with teicoplanin.

M Fernández-Guerrero1, M Gobernado, J Ariza

  • 1Fundación Jiménez Diaz, Madrid, Spain.

Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myocardial abscess: an unusual complication of long-term hemodialysis line presence.

Clinical nephrology·1999
Same author

"One-stop" surgery: implications for anesthesiologists of an expedited pediatric surgical process.

Southern medical journal·1999
Same author

Calculating the global burden of disease: time for a strategic reappraisal?

Health economics·1999
Same author

Aerosol route enhances the contamination of intact eggs and muscle of experimentally infected laying hens by Salmonella typhimurium DT104.

FEMS microbiology letters·1999
Same author

Short gastric artery perforation after use of 'ecstasy'.

Journal of the Royal Society of Medicine·1999
Same author

Meniscal movement. An in-vivo study using dynamic MRI.

The Journal of bone and joint surgery. British volume·1999
Same journal

Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.

Scandinavian journal of infectious diseases. Supplementum·2009
Same journal

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.

Scandinavian journal of infectious diseases. Supplementum·2009
Same journal

Supreme Court decision on genotypic tests for antiretroviral drugs resistance: Joint Criminal Divisions.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Brief summary of the legal proceeding.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Too early or too late: a never-ending dilemma with new technologies.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Genotypic resistance tests for the management of postexposure prophylaxis.

Scandinavian journal of infectious diseases. Supplementum·2004
See all related articles

Teicoplanin, a narrow-spectrum glycopeptide antibiotic, demonstrated efficacy in treating severe infections, with a 75% clinical cure rate. The antibiotic exhibited an acceptable safety profile, with mild to moderate adverse events in most patients.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Microbiology

Background:

  • Teicoplanin is a narrow-spectrum glycopeptide antibiotic used for severe bacterial infections.
  • Limited data existed on its prospective evaluation in diverse severe infections.

Purpose of the Study:

  • To prospectively evaluate the efficacy and safety of teicoplanin in treating various severe infections.
  • To assess teicoplanin's effectiveness against common pathogens like Staphylococcus aureus.

Main Methods:

  • An open, non-comparative study was conducted across three Spanish university hospitals.
  • Sixty-five patients with severe infections received teicoplanin, with median dose and duration recorded.
  • Microbiological and clinical outcomes were assessed, along with adverse events.

Related Experiment Videos

Main Results:

  • Teicoplanin therapy eliminated 44 out of 70 isolated organisms, with Staphylococcus aureus being most common.
  • A 75% clinical cure rate was observed, with 11% showing improvement and 11% treatment failure.
  • Sixteen out of 65 patients experienced adverse events, mostly mild to moderate, indicating acceptable safety.

Conclusions:

  • Teicoplanin is effective and safe for treating severe infections, particularly those caused by Staphylococcus aureus.
  • The safety profile is confirmed, even at doses around 6 mg/kg.
  • Further comparative studies against standard antibiotic regimens are warranted.